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S U M M A R Y
Background: The objective of this study was to examine the clinical and immunological features of
cholera in pregnancy.
Methods: Women of reproductive age presenting to the icddr,b Dhaka hospital with cholera, and
enrolled as part of a larger cohort study, were tested for pregnancy on admission. We compared initial
clinical features and immune responses of pregnant patients with non-pregnant female patients at days
2, 7 and 21 after infection.
Results: Among reproductive age women enrolled between January 2001 and May 2006, 9.7% (14/144)
were pregnant. The duration of diarrhoea prior to admission tended to be higher in pregnant compared
to non-pregnant patients (p=0.08), but other clinical characteristics did not differ. Antibody responses to
cholera toxin B subunit (CtxB), toxin-coregulated pilus A (TcpA), Vibrio cholerae lipopolysaccharide (LPS),
and serum vibriocidal antibody responses, were comparable between pregnant and non-pregnant
patients. There were no deaths among the pregnant cases or non-pregnant controls, and no adverse
foetal outcomes, including stillbirths, during 21 days of follow up of pregnant cases.
Conclusions: To our knowledge, this is the ﬁrst report of immune responses in pregnant women with
cholera. We found that pregnant woman early in pregnancy has comparable clinical illness and
subsequent immune responses compared to non-pregnant women. These ﬁndings suggest that the
evaluation of safety and immunogenicity of oral cholera vaccines in pregnancy should be an area of
future investigations.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Cholera is a life threatening diarrheal disease caused predomi-
nantly by infection with Vibrio cholerae O1. Though cholera is rare
in developed countries, it is prevalent in many areas of South and
Southeast Asia and in Africa and may also cause major outbreaks
worldwide.1 Bangladesh is a country in South Asia where cholera is
endemic and is consistently present throughout the year in high* Corresponding author. Centre for Vaccine Sciences, icddr,b, 68 Shahid Tajuddin
Ahmed Sarani, Mohakhali, Dhaka 1212, Bangladesh. Tel.: +880 2 9827001 10;
fax: +880 2 8823116/2 8826050x2431.
E-mail address: fqadri@icddrb.org (F. Qadri).
http://dx.doi.org/10.1016/j.ijid.2015.08.006
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).risk areas.2 Cholera toxin (CT), the primary toxin produced by V.
cholerae O1 and O139, causes the hypersecretion of electrolytes
and water, sometimes with fatal results. The lipopolysaccharide of
V. cholerae is an important determinant of protection, and is the
primary antigen found in the most recent formulations of the oral
cholera vaccine (OCV).
Pregnancy is an immuno-altered state where both humoral and
cellular immunity are affected.3,4 Several pregnancy outcomes,
including preeclampsia, poor foetal growth, and preterm birth,
have been linked to abnormalities in immune responses during
pregnancy.5–7 Pregnancy has also been associated with decreased
inﬂammatory responses and increased anti-inﬂammatory
responses to immune challenges in humans as well as in animal
models.8,9 In some cases, pregnant women are more susceptible tociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Clinical and microbiological features of pregnant and all non-pregnant study
participants
Characteristics Pregnant
(n=14)
Non-pregnant
(n=130)
p-value
Demographics
Median age (yr),
(25th, 75th percentile)
24.5 (21 - 29) 27 (21 - 36) 0.14
Blood group, n (%)
O 4 (28.6) 58 (44.6)
A 2 (14.3) 36 (27.7)
B 6 (42.9) 31 (23.9)
AB 2 (14.3) 5 (3.9) 0.09
Clinical
Dehydration
Some 1 (7.1) 9 (6.9)
Severe 13 (92.9) 121 (93.18) 1.00
No. of stools (> 20 in last 24hrs) 10 (71.4) 111 (85.48) 0.24
Fever in the last week 2 (14.3) 27 (20.8) 0.74
Vomiting in the last 24hrs
No or <10 times 5 (35.7) 65 (50.0)
 10 times 9 (64.3) 65 (50.0) 0.40
Abdominal pain at presentation 11 (78.6) 93 (71.5) 0.76
Helminth present 2 (14.3) 16 (12.3) 0.69
Received IV ﬂuid 13 (92.9) 126 (96.9) 0.41
Duration of diarrhoea, hr
Median (IQR) 100 (9 - 105) 12 (7 - 23) 0.08
Duration of stay, hr
Median (IQR) 102 (41 - 104) 103 (100 - 105) 0.25
Microbiological, n (%)
Dark ﬁeld positive stool
V. cholerae O1, Ogawa 3 (21.4) 41 (31.5) 0.55
V. cholerae O1, Inaba 7 (50.0) 66 (50.8) 1.00
V. cholerae O139 4 (28.6) 23 (17.7) 0.30
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severity of illness. For example, pregnant women infected with
inﬂuenza virus are at increased risk for serious complications when
compared to other groups,10 though a recent study on inﬂuenza
virus vaccine during pregnancy showed that pregnancy did not
signiﬁcantly alter antibody responses.11
Women living in areas endemic for cholera are at risk of
acquiring the disease during pregnancy, and studies from South
Asia, Africa, and Haiti have demonstrated that cholera during
pregnancy may increase the risk of poor outcomes.12 However,
there is a lack of data on the immunological responses to cholera
during pregnancy to determine if vaccination might play a role in
prevention. Thus, the objective of this study was to examine the
clinical characteristics and immunological responses of pregnant
women following severe cholera.
2. Materials and Methods
2.1. Study population and patient enrolment
The Cholera Immune Response Study (CIRS) was a prospective,
observational study, undertaken as a collaboration between the
International Centre for Diarrhoeal Disease Research, Bangladesh
(icddr,b) and Massachusetts General Hospital in Boston. The
icddr,b in Dhaka, Bangladesh cares for approximately 120,000
patients with diarrheal diseases each year. Patients presenting to
the icddr,b Dhaka hospital with acute watery diarrhoea (study day
1) were eligible for inclusion in this study if their stool cultures
were subsequently positive for V. cholerae, and if they were
without signiﬁcant co-morbid conditions; patients were enrolled
prospectively in the study between 2001 and 2006.13,14 Stool
cultures for V. cholerae were done on taurocholate-tellurite-gelatin
agar (TTGA). After overnight incubation of plates, serological
conﬁrmation of suspected V. cholerae colonies was carried out by
slide agglutination.15 Patients were enrolled on day 2 of admission
(study day 2) if a stool culture was positive for V. cholerae O1 or
O139. Information regarding clinical features, demographics, and
history of diarrhoea were collected from patients at enrolment.
Samples of venous blood were collected, for determining antibody
titers, from patients on study day 2 and again at follow-up visits on
study days 7 and 21. Informed written consent for participation in
this research was obtained from participants or their guardians.
This study was reviewed and approved by the Ethical and Research
Review Committees of the icddr,b and the Institutional Review
Board of the Massachusetts General Hospital.
2.2. Pregnant women and case control comparison
All women of reproductive age (15-49) enrolled in the CIRS
study were screened for pregnancy by urine strip test (hCG One
Step Pregnancy Test Strip, TUV product service, USA) on enrolment.
A total of 14 women had a positive pregnancy test. We also
selected all non-pregnant cases as controls from the same age
cohort.
2.3. Treatment of patients
Patients enrolled for the study received the normal standard of
care provided at the icddr,b for cholera. Dehydration was corrected
either by infusing intravenous cholera saline or by oral rehydration
solution depending on the severity of the dehydration and clinical
condition of the patient. A short course of oral antibiotics was
given. Non pregnant adult females with stool culture positive for V.
cholerae received 300 mg of doxycycline in a single dose, whereas
pregnant women with cholera received erythromycin (500 mg
every six hours) for three days.2.4. Immunological assessment
We measured vibriocidal antibodies in patient plasma using V.
cholerae O1 El Tor Ogawa (strain X25049) or Inaba (strain 19479)
or V. cholerae O139 (strain 4260B) as target bacteria, and adding
guinea pig complement.16 Antibody responses to recombinant
cholera toxin B subunit (CtxB), toxin-coregulated pilus A subunit
(TcpA), and lipopolysaccharide (LPS) were determined using a
kinetic enzyme-linked immunosorbent assay (ELISA), as previous-
ly described.17 In all cases, the vibriocidal and LPS responses were
measured to the same serotype, Ogawa or Inaba of V. cholerae O1
and V. cholerae O139 as was present in the patient.
2.5. Data analyses
Data analyses were performed using SPSS for Windows (version
12; SPSS Inc., Chicago, IL, USA) and Epi Info (version 6.0; USD, Stone
Mountain, GA, USA). For non-normally distributed data, compar-
isons were carried out as median (25th–75th percentile) using the
Mann–Whitney U-test. The signiﬁcance of differences in propor-
tions was evaluated by the Chi-square test, and Fisher’s exact test
was applied when appropriate. A p-value of <0.05 was considered
statistically signiﬁcant.
3. Results
A total of 399 patients with cholera were enrolled in the study
between January 2001 and May 2006 and the data obtained
prospectively were analysed in a retrospective fashion. Overall,
144 cholera patients were reproductive age (15-49 years) women
and of those, 9.7% (14/144) had a positive pregnancy test. Average
duration of pregnancy was 14 weeks at enrolment (minimum
6 weeks, maximum 24 weeks, mean SD = 145.6 weeks) (data not
shown). The clinical and microbiological features of the pregnant and
non-pregnant cholera cases are presented in Table 1.
Table 2
Vibriocidal antibody responses of study participants by pregnancy status
Infecting strain Antibody Pregnant (n=14) Non-pregnant (n=130) p-value
Vibriocidal
(*Study Days)
n Median (IQR) n Median (IQR)
Overall Day 2 14 80 (10 - 640) 128 80 (20 - 160) 0.84
Day 7 14 2560 (1280 - 8960) 122 5120 (2560 - 10240) 0.32
Day 21 11 2560 (640 - 5120) 120 2560 (1280 - 5120) 0.66
V.cholerae O1 Day 2 10 480 (50 - 640) 105 80 (40 - 320) 0.19
Day 7 10 3840 (2560,17920) 99 5120 (2560 - 10240) 0.97
Day 21 9 5120 (1280,5120) 97 5120 (1280 - 5120) 0.95
V. cholerae O139 Day 2 4 8 (5 -,28) 23 20 (10 - 80) 0.27
Day 7 4 640 (520 - 800) 23 1280 (640 - 2560) 0.10
Day 21 2 163 (84 - 241) 23 640 (640 - 1280) 0.05
* Patients presenting to the icddr,b Dhaka hospital with acute watery diarrhoea (study day 1); Antibody titers, from patients at baseline on study day 2 and again at follow-
up visits on study days 7 and 21.
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higher (p=0.08) in the pregnant cohort compared to the non-
pregnant control cohort of patients with cholera. However, other
clinical parameters, including severity of dehydration and volume
of intravenous ﬂuids required, did not differ between the pregnant
and non-pregnant cholera cases (Table 1). There were no deaths
among the pregnant cases or non-pregnant controls, and no
adverse foetal outcomes including spontaneous abortions in the
21 days following cholera in the pregnant women.
We assessed the association between the baseline (Day 2) and
convalescent stage (Day 7 and 21) responses in a number of
immunologic markers and pregnancy status of cholera patients.
Serum vibriocidal titers (Table 2), as well as antibody responses to
LPS, CtxB, and TcpA (Table 3, 4, 5), showed no statistically
signiﬁcant differences between pregnant and non-pregnant
patients overall. However, when we compared responses sepa-
rately for V. cholerae O1 and O139 infected patients, serumTable 3
Responses to LPS of study participants by pregnancy status
Infecting
strain
Antibody
(*Study
Days)
Pregnant
(n=14)
Non-pregnant
(n=130)
p-value
n Median (IQR) n Median (IQR)
Overall LPS IgA
Day 2 14 22 (18 - 31) 130 22 (12 - 39) 0.95
Day 7 14 103 (32 - 250) 124 151 (73 - 268) 0.26
Day 21 11 81(30 - 177) 120 97 (49 - 184) 0.49
LPS IgG
Day 2 14 72 (47 - 122) 130 79 (55 - 106) 0.87
Day 7 14 180 (98 - 248) 124 227 (164 - 292) 0.12
Day 21 11 258 (106 - 283) 120 238 (150 - 313) 0.30
V.cholerae
O1
LPS IgA
Day 2 10 24 (19 - 31) 107 21 (11 - 37) 0.49
Day 7 10 169 (87 - 308) 101 162 (74 - 293) 0.97
Day 21 9 106 (30 - 184) 97 89 (43 - 200) 0.80
LPS IgG
Day 2 10 99 (60 - 138) 107 75 (55 - 103) 0.30
Day 7 10 224 (158 - 259) 101 226 (163 - 297) 0.73
Day 21 9 268 (123 - 298) 97 230 (146 - 318) 0.91
V. cholerae
O139
LPS IgA
Day 2 4 21 (14 - 26) 23 30 (14 - 42.67) 0.25
Day 7 4 38 (21 - 54.17) 23 102 (64 - 170) 0.02
Day 21 2 47 (38 - 55.33) 23 117 (68 - 158) 0.09
LPS IgG
Day 2 4 53 (37 - 64) 23 90 (72 - 111) 0.02
Day 7 4 107 (81 - 130) 23 228 (195 - 277) 0.01
Day 21 2 83 (75 - 91) 23 246 (219 - 300) 0.03
* Patients presenting to the icddr,b Dhaka hospital with acute watery diarrhoea
(study day 1); Antibody titers, from patients at baseline on study day 2 and again at
follow-up visits on study days 7 and 21.vibriocidal responses and as well as antibody response to LPS and
CtxB were higher in non-pregnant women compared to pregnant
women infected with V. cholerae O139 (Tables 2, 3, 4).
4. Discussion
This is the ﬁrst report to our knowledge of immune responses
following cholera in pregnant women. We found that overall, most
of the clinical and immunological characteristics were comparable
between pregnant and non-pregnant women presenting to the
icddr,b hospital with severe cholera. When analysed separately for
patients infected with V .cholerae O1 versus O139, the vibriocidal
antibody responses following O1 infection were more robust in
general than those seen following O139 infection, as we have seen
earlier.16 Serum vibriocidal responses as well as antibody
responses to LPS, CtxB and TcpA were similar between pregnantTable 4
Responses to CtxB of study participants by pregnancy status
Infecting
strain
Antibody
(*Study
Days)
Pregnant
(n=14)
Non-pregnant
(n=130)
p-value
n Median (IQR) n Median (IQR)
Overall CtxB IgA
Day 2 14 19 (16 - 38) 130 22 (12 - 44) 0.75
Day 7 14 92 (58 - 160) 124 123 (65 - 204) 0.49
Day 21 11 56 (48 - 115) 120 71 (41 - 125) 0.89
CtxB IgG
Day 2 14 109 (75 - 131) 130 98 (61 - 157) 0.87
Day 7 14 288 (213 - 352) 124 260 (194 - 425) 0.98
Day 21 11 369 (252 - 401) 120 285 (213 - 399) 0.40
V.cholerae
O1
CtxB IgA
Day 2 10 20 (16 - 60) 107 22 (12 - 41) 0.75
Day 7 10 92 (64 - 156) 101 111 (57 - 175) 0.96
Day 21 9 68 (48 - 135) 97 67 (36 - 100) 0.44
CtxB IgG
Day 2 10 117 (85 - 131) 107 99 (63 - 160) 0.70
Day 7 10 288 (266 - 347) 101 260 (191 - 411) 0.52
Day 21 9 378 (281 - 411) 97 286 (202 - 410) 0.13
V. cholerae
O139
CtxB IgA
Day 2 4 19 (16 - 20) 23 25 (15 - 49) 0.19
Day 7 4 97 (52 - 151) 23 191 (129 - 304) 0.08
Day 21 2 50 (49 - 51) 23 107 (74 - 176) 0.04
CtxB IgG
Day 2 4 92 (63 - 119) 23 75 (53 - 132) 1.00
Day 7 4 231 (124 - 327) 23 260 (219 - 430) 0.25
Day 21 2 180 (151 - 209) 23 282 (234 - 385) 0.11
* Patients presenting to the icddr,b Dhaka hospital with acute watery diarrhoea
(study day 1); Antibody titers, from patients at baseline on study day 2 and again at
follow-up visits on study days 7 and 21.
Table 5
Responses to TcpA of study participants by pregnancy status
Infecting
strain
Antibody
(Study
Days)
Pregnant
(n=14)
Non-pregnant
(n=130)
p-value
n Median (IQR) n Median (IQR)
Overall TcpA IgA
Day 2 9 5 (2 - 5) 79 6 (3 - 11) 0.08
Day 7 9 13 (7 - 33) 77 22 (7 - 46) 0.91
Day 21 9 12 (9 - 37) 76 11 (6 - 26) 0.26
TcpA IgG
Day 2 7 30 (20 - 40) 58 40 (24 - 65) 0.21
Day 7 7 66 (65 - 142) 56 64 (35 - 128) 0.41
Day 21 7 90 (58 - 130) 55 77 (44 - 120) 0.47
V.cholerae
O1
TcpA IgA
Day 2 7 3 (2 - 5) 68 6 (3 - 11) 0.07
Day 7 7 13 (6 - 23) 66 23 (6 - 46) 0.62
Day 21 7 12 (10 - 35) 65 13 (6 - 27) 0.44
TcpA IgG
Day 2 6 26 (20 - 35) 57 42 (24 - 65) 0.15
Day 7 6 66 (64 - 110) 55 56 (35 - 123) 0.65
Day 21 6 100 (51 - 131) 54 76 (40 - 122) 0.46
V. cholerae
O139
TcpA IgA
Day 2 2 5 (4.6 - 4.9) 11 5 (4 - 5) 1.00
Day 7 2 104 (57 - 152) 11 14 (7 - 36) 0.43
Day 21 2 47 (28 - 66) 11 10 (8 - 11) 0.43
Tcp IgG
Day 2 1 43 (43 - 43) 1 26 (26 - 26) 0.32
Day 7 1 160 (160 - 160) 1 127 (127 - 127) 0.32
Day 21 1 90 (90 - 90) 1 101 (101 - 101) 0.32
* Patients presenting to the icddr,b Dhaka hospital with acute watery diarrhoea
(study day 1); Antibody titers, from patients at baseline on study day 2 and again at
follow-up visits on study days 7 and 21.
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women infected with V. cholerae O139 had lower serum vibriocidal
responses and antibody responses to LPS and CtxB compared to
non-pregnant women infected with this serogroup. This study also
found no deaths among the pregnant cases or non-pregnant
controls, and no adverse foetal outcomes during 21 days of follow
up of the pregnant cases. Of note, our follow up period was limited
to 21 days after infection, and the infected pregnant women were
in the ﬁrst or second trimester.
In a study from Haiti, a previously non-endemic area, analysis of
outcome data from a large cohort of pregnant women with cholera
revealed that the main risk factor for foetal death was severity of
dehydration.12 Although our study did not follow the outcome of
pregnancy for more than the 21 day follow up period after the
episode of cholera, we did not ﬁnd any difference in the severity of
dehydration between pregnant and non-pregnant women pre-
senting in the ﬁrst or second trimester with severe cholera. At
icddr,b severe dehydration is immediately corrected with cholera
saline following presentation to the facility. The management of
individuals with cholera involves ﬂuid resuscitation based on the
level of dehydration and then after adequate hydration, mainte-
nance of ongoing ﬂuid losses.18 Cholera in the third trimester has
previously been signiﬁcantly associated with an increased severity
of diarrhoeal disease, as indicated by severe dehydration on
admission to hospital, as compared with non-pregnant controls.19
Several studies also suggest an association between foetal loss and
the degree of dehydration and hypovolemia.19–21 Independent of
the dehydration status, severe vomiting was also found to be
another risk factor for foetal death.12 Changes in electrolytes in the
amniotic ﬂuid of pregnant women suffering from cholera have
been described in the literature,22 but it remains unclear how these
affect the foetus. In our study, it is notable that vomiting was not
signiﬁcantly different between pregnant patients in the ﬁrst and
second trimester and non-pregnant cholera patients.The serum vibriocidal antibody assay has been used to measure
the antibacterial antibody response in cholera patients and
elevated vibriocidal antibody levels have been shown to correlate
with protection against cholera.16,23,24 This has led to the use of
serum vibriocidal antibody responses as a surrogate marker for
cholera vaccine efﬁcacy. In our study, serum vibriocidal responses
did not differ between pregnant and non-pregnant cholera
patients infected with V. cholerae O1, the major currently
circulating serogroup.
LPS is an important antigen for enteric pathogens and responses
to LPS appear to be involved in protection against cholera.25 For
example, V. cholerae O1 LPS has been shown to induce protective
immune responses in humans and animals26,27 and thus its use as a
protective immunogen for cholera vaccine development has been
widely accepted.28,29 We did not ﬁnd any statistically signiﬁcant
differences in LPS antibody responses between pregnant and non-
pregnant cholera patients infected with V. cholerae O1. In cholera-
endemic countries like Bangladesh, vaccinating the entire popula-
tion may not be possible. However vaccination can be targeted in
high-risk areas and to select high-risk populations that are
especially vulnerable to severe disease; these targeted groups
might include pregnant women if the vaccine is found to be safe in
pregnancy. One recent study in Zanzibar found no statistically
signiﬁcant evidence of a harmful effect of gestational exposure to
oral cholera vaccine.30 Thus the evaluation of oral cholera vaccines
and subsequent use in pregnant women should be considered an
important priority.
The main limitation of this study is the fact that the cohort
consisted of only patients with severe cholera requiring hospitali-
zation. Since many cases of infection with V. cholerae O1 do not
result in severe infection, the association between pregnancy and
the full spectrum of disease severity cannot be gauged in this
study. Another limitation of this study is that we had a small
sample size (14 pregnant women with cholera) and only followed
pregnancy outcomes until 21 days after infection and we did not
gather data on later foetal outcomes. Also, we did not assess
mucosal immune responses using the antibody-secreting cell or
antibody-in-lymphocyte supernatant assay for all the patients in
this study. As most of the pregnant women were in the initial stage
of gestation (average duration of pregnancy was 14 weeks), this
may explain why the women had similar clinical severity unlike
other studies later in pregnancy. The small sample size of pregnant
women assessed for clinical severity, as well as the inclusion of
only women with severe cholera, suggest that we did not have
sufﬁcient power for a full accounting of the severity of disease in
pregnancy. Despite these limitations, to our knowledge, our study
represents a unique analysis of immune responses to cholera
during pregnancy.
In conclusion, we have shown that pregnant women with
severe cholera due to V. cholerae O1 respond immunologically in a
similar manner to non-pregnant women despite the immune
alterations associated with pregnancy. Our data underscore the
fact that pregnant women with cholera are able to mount normal
vibriocidal and other anti-V. cholerae immune responses. These
ﬁndings suggest that the evaluation of safety and immunogenicity
of oral cholera vaccines in pregnancy should be an area of future
investigations so that the use of oral killed cholera vaccine in
pregnant women at risk of cholera can be considered.
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